Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRIS NASDAQ:NTGN NASDAQ:SABS NASDAQ:SGMO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRISCuris$1.63-1.8%$2.08$1.02▼$8.29$17.05M3.66124,260 shs60,478 shsNTGNNeon Therapeutics$3.07$3.03$0.88▼$6.25$88.93M-0.81516,108 shsN/ASABSSAB Biotherapeutics$2.23+18.6%$2.07$1.00▼$6.60$20.71M0.534.31 million shs258,761 shsSGMOSangamo Therapeutics$0.56+4.6%$0.51$0.41▼$3.18$130.95M1.185.73 million shs4.20 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRISCuris0.00%-11.41%-11.41%-32.37%-70.26%NTGNNeon Therapeutics0.00%0.00%0.00%0.00%0.00%SABSSAB Biotherapeutics0.00%-12.55%+28.90%+39.38%-19.65%SGMOSangamo Therapeutics0.00%-4.10%+4.78%-22.89%-28.24%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRISCuris1.7644 of 5 stars3.53.00.00.00.80.00.6NTGNNeon TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ASABSSAB Biotherapeutics3.4577 of 5 stars3.54.00.00.03.41.71.3SGMOSangamo Therapeutics1.5181 of 5 stars3.32.00.00.00.60.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRISCuris 3.00Buy$17.00942.94% UpsideNTGNNeon Therapeutics 0.00N/AN/AN/ASABSSAB Biotherapeutics 3.00Buy$13.00482.96% UpsideSGMOSangamo Therapeutics 2.67Moderate Buy$4.50701.28% UpsideCurrent Analyst Ratings BreakdownLatest CRIS, SABS, NTGN, and SGMO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/22/2025SABSSAB BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$10.00 ➝ $9.006/24/2025SGMOSangamo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.005/19/2025CRISCurisHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$17.005/15/2025SABSSAB BiotherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.005/14/2025SABSSAB BiotherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/14/2025SGMOSangamo TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$9.00 ➝ $5.00(Data available from 8/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRISCuris$10.91M1.56N/AN/A($0.71) per share-2.30NTGNNeon TherapeuticsN/AN/AN/AN/A$0.50 per shareN/ASABSSAB Biotherapeutics$1.32M15.69N/AN/A$2.81 per share0.79SGMOSangamo Therapeutics$57.80M2.27N/AN/A$0.11 per share5.11Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRISCuris-$43.39M-$6.23N/AN/AN/A-376.08%N/A-97.14%8/5/2025 (Estimated)NTGNNeon Therapeutics-$79.78M-$2.86N/AN/AN/AN/A-199.09%-137.14%N/ASABSSAB Biotherapeutics-$34.10M-$3.70N/AN/AN/AN/A-105.14%-69.24%8/6/2025 (Estimated)SGMOSangamo Therapeutics-$97.94M-$0.39N/AN/AN/A-124.61%-345.98%-79.86%8/7/2025 (Estimated)Latest CRIS, SABS, NTGN, and SGMO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025SABSSAB Biotherapeutics-$0.66N/AN/AN/AN/AN/A8/7/2025Q2 2025SGMOSangamo Therapeutics-$0.07N/AN/AN/A$31.68 millionN/A8/5/2025Q2 2025CRISCuris-$1.99N/AN/AN/A$2.64 millionN/A5/12/2025Q1 2025SGMOSangamo Therapeutics-$0.11-$0.14-$0.03-$0.14$7.90 million$6.44 million5/9/2025Q1 2025SABSSAB Biotherapeutics-$1.00-$0.56+$0.44-$0.56$0.13 millionN/A5/6/2025Q1 2025CRISCuris-$1.14-$1.25-$0.11-$1.25$2.37 million$2.38 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRISCurisN/AN/AN/AN/AN/ANTGNNeon TherapeuticsN/AN/AN/AN/AN/ASABSSAB BiotherapeuticsN/AN/AN/AN/AN/ASGMOSangamo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRISCurisN/A1.231.23NTGNNeon Therapeutics0.431.583.00SABSSAB Biotherapeutics0.151.691.69SGMOSangamo TherapeuticsN/A0.760.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRISCuris29.97%NTGNNeon Therapeutics54.71%SABSSAB Biotherapeutics7.82%SGMOSangamo Therapeutics56.93%Insider OwnershipCompanyInsider OwnershipCRISCuris5.45%NTGNNeon Therapeutics38.93%SABSSAB Biotherapeutics27.77%SGMOSangamo Therapeutics4.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRISCuris6010.46 million9.89 millionNo DataNTGNNeon Therapeutics10228.97 millionN/ANot OptionableSABSSAB Biotherapeutics1409.29 million6.71 millionNot OptionableSGMOSangamo Therapeutics480233.17 million223.61 millionOptionableCRIS, SABS, NTGN, and SGMO HeadlinesRecent News About These CompaniesSangamo Therapeutics Announces Second Quarter 2025 Earnings CallJuly 31 at 4:05 PM | globenewswire.comContrasting Inovio Pharmaceuticals (NASDAQ:INO) and Sangamo Therapeutics (NASDAQ:SGMO)July 31 at 4:09 AM | americanbankingnews.comSangamo Therapeutics (SGMO) Expected to Announce Quarterly Earnings on TuesdayJuly 30, 2025 | marketbeat.comSangamo Therapeutics Announces Positive Phase 1/2 STAAR Study Results for Fabry Gene TherapyJuly 25, 2025 | msn.comSangamo Therapeutics, Inc. (NASDAQ:SGMO) Given Consensus Recommendation of "Moderate Buy" by AnalystsJuly 19, 2025 | marketbeat.comH.C. Wainwright Reaffirms Buy Rating on Sangamo After Promising Gene Therapy DataJuly 3, 2025 | msn.comSGMO - Sangamo Therapeutics Inc Trailing Returns - MorningstarJuly 2, 2025 | morningstar.comMSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - MorningstarJune 25, 2025 | morningstar.comMSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry Disease - Business WireJune 25, 2025 | businesswire.comSangamo cues up Fabry gene therapy filing on STAAR dataJune 25, 2025 | pharmaphorum.comPSangamo Therapeutics, Inc.: Sangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry DiseaseJune 24, 2025 | finanznachrichten.deSangamo preps FDA application for Fabry gene therapy on heels of phase 1/2 registrational dataJune 24, 2025 | fiercebiotech.comFSangamo rises after trial data for Fabry disease therapyJune 24, 2025 | msn.comSangamo Therapeutics Announces Positive Topline Results From Registrational STAAR Study in Fabry DiseaseJune 24, 2025 | businesswire.comH.C. Wainwright Maintains Buy Rating on Sangamo Therapeutics (SGMO)May 31, 2025 | insidermonkey.comSangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call TranscriptMay 12, 2025 | seekingalpha.comSangamo Therapeutics Postpones First Quarter 2025 Conference Call to Later the Same DayMay 12, 2025 | finance.yahoo.comSangamo Therapeutics (SGMO) Reports Q1 Loss, Misses Revenue EstimatesMay 12, 2025 | zacks.comSangamo Therapeutics Reports Recent Business Highlights and First Quarter 2025 Financial ResultsMay 12, 2025 | businesswire.comSangamo Therapeutics Announces Pricing of $23.0 Million Underwritten OfferingMay 12, 2025 | businesswire.comSangamo Therapeutics Q1 2025 Earnings PreviewMay 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRIS, SABS, NTGN, and SGMO Company DescriptionsCuris NASDAQ:CRIS$1.63 -0.03 (-1.81%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.64 +0.01 (+0.31%) As of 08/1/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single arm expansion trial in patients with relapsed or refractory, or R/R, AML and high-risk myelodysplastic syndromes. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3. It has collaboration agreement with Genentech Inc., or Genentech and F. Hoffmann-La Roche Ltd, or Roche, for the commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma, or BCC; Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology; and also licensed four programs under the Aurigene collaboration, including emavusertib. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.Neon Therapeutics NASDAQ:NTGNNeon Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.SAB Biotherapeutics NASDAQ:SABS$2.23 +0.35 (+18.62%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$2.22 0.00 (-0.22%) As of 08/1/2025 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases. The company also uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors or plasma. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 1 trials in delaying the onset or progression of type 1 diabetes. Further, the company develops SAB-176, a multivalent, broadly neutralizing - human polyclonal immunoglobulin therapeutic candidate, currently in Phase 2a development for the treatment or prevention of severe influenza. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.Sangamo Therapeutics NASDAQ:SGMO$0.56 +0.02 (+4.56%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.56 0.00 (-0.28%) As of 08/1/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
